Efficacy of the current investigational drugs for the treatment of COVID-19 : a scoping review

To date, there is no final FDA-approved treatment for COVID-19. There are thousands of studies published on the available treatments for COVID-19 virus in the past year. Therefore, it is crucial to synthesize and summarize the evidence from published studies on the safety and efficacy of experimental treatments of COVID-19. We conducted a systematic literature search of MEDLINE, PubMed, Cochrane Library, GHL, OpenGrey, ICTRP, and ClinicalTrials.gov databases through April 2020. We obtained 2699 studies from the initial literature search. Of them, we included 28 eligible studies that met our eligibility criteria. The sample size of the included studies is 2079 individuals. We extracted and pooled the available data and conducted a quality assessment for the eligible studies. From the 28 studies, only 13 studies provide strong evidence. Our results showed that Favipiravir and Hydroxycholoroquine shorten viral clearance and clinical recovery time and promote pneumonia absorption. On the other hand, Lopinavir-ritonavir either alone or combined with arbidol or interferons has no significant difference superior to the standard care. Corticosteroids, Convalescent plasma transfusion, and anticoagulant therapies provide a better prognosis. Remedsivir, Tocilizumab, Immunoglobulin, Mesenchymal stem cell transplantation showed effective treatment results, but further confirmatory studies are needed. In conclusion, Favipiravir and Remedsivir might be promising drugs in the treatment of COVID-19 patients. .

Media Type:

Electronic Article

Year of Publication:

2021

Contained In:

Annals of medicine - Vol. 53, No. 1 (2021), p. 318-334

Language:

English

Contributors:

Wadaa-Allah, Ahmed
Emhamed, Marwa S
Sadeq, Mohammed A
Ben Hadj Dahman, Nesrine
Ullah, Irfan
Farrag, Nesrine S
Negida, Ahmed

Links:

Volltext

Keywords:

*Drugs, Investigational
COVID-19
Coronavirus
Drugs
Drugs, Investigational
Humans
Journal Article
Research Support, Non-U.S. Gov't
SARS-COV-2
Systematic Review
Treatment
Treatment Outcome

Notes:

Date Completed 08.04.2021

Date Revised 22.04.2021

published: Print

Citation Status MEDLINE

Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Physical Description:

Online-Ressource

doi:

10.1080/07853890.2021.1875500

PMID:

33706639

PPN (Catalogue-ID):

NLM323715109